Jazz Pharmaceuticals PLC
NASDAQ:JAZZ

Watchlist Manager
Jazz Pharmaceuticals PLC Logo
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Watchlist
Price: 125.82 USD 1.69% Market Closed
Market Cap: 7.6B USD
Have any thoughts about
Jazz Pharmaceuticals PLC?
Write Note

Jazz Pharmaceuticals PLC
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jazz Pharmaceuticals PLC
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Short-Term Investments
$400m
CAGR 3-Years
45%
CAGR 5-Years
-12%
CAGR 10-Years
-4%
Perrigo Company PLC
NYSE:PRGO
Short-Term Investments
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Short-Term Investments
$37.2m
CAGR 3-Years
-33%
CAGR 5-Years
-9%
CAGR 10-Years
-3%
Cosmo Pharmaceuticals NV
SIX:COPN
Short-Term Investments
€78.9m
CAGR 3-Years
51%
CAGR 5-Years
-14%
CAGR 10-Years
12%
Ovoca Bio PLC
LSE:OVB
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jazz Pharmaceuticals PLC
Glance View

Market Cap
7.6B USD
Industry
Pharmaceuticals

In the bustling world of global pharmaceuticals, Jazz Pharmaceuticals PLC has carved out a niche for itself through its focus on specialty pharmaceuticals addressing unmet medical needs. Founded in 2003, Jazz has grown significantly by acquiring and developing unique products that serve smaller patient populations but address significant health challenges. Its journey is one of careful strategy and thoughtful innovation. The company first gained attention with its sleep disorder portfolio, most notably Xyrem, a treatment for narcolepsy that quickly became a cornerstone of its revenue stream. Jazz's adeptness at navigating complex regulatory and market environments has played a crucial role in its success, allowing it to maintain a stronghold in niche therapeutic markets. Building on its initial successes, Jazz began to diversify its portfolio, expanding into oncology and neuroscience. The acquisition of companies like Celator Pharmaceuticals and GW Pharmaceuticals was a strategic move to broaden its research capabilities and tap into the lucrative, yet challenging, segments of cancer and cannabinoid therapies. Jazz’s pipeline is rich with promising candidates, reflecting its commitment to long-term growth through innovation. Central to its business model is the commercialization of these specialized, high-value drugs, which are marketed to healthcare providers and directly impact patient outcomes. By focusing on diseases with few effective treatments, Jazz positions itself as a leader in transforming lives, all while sustaining its financial health through carefully managed margins and a global reach in its distribution and research efforts.

JAZZ Intrinsic Value
361.23 USD
Undervaluation 65%
Intrinsic Value
Price

See Also

What is Jazz Pharmaceuticals PLC's Short-Term Investments?
Short-Term Investments
400m USD

Based on the financial report for Sep 30, 2024, Jazz Pharmaceuticals PLC's Short-Term Investments amounts to 400m USD.

What is Jazz Pharmaceuticals PLC's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
-4%

Over the last year, the Short-Term Investments growth was -51%. The average annual Short-Term Investments growth rates for Jazz Pharmaceuticals PLC have been 45% over the past three years , -12% over the past five years , and -4% over the past ten years .

Back to Top